Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% Higher - Still a Buy?

Key Points

• Shares jumped 8.7% to about $13.40 on Wednesday, but volume was tiny (~18,205 shares), roughly a 94% drop from the stock's average daily trading volume.
• Analyst views are mixed: the consensus is a "Moderate Buy" with an average price target of $19.50, while individual notes range from Morgan Stanley's $14 target to Robert W. Baird's $20 and ratings span Buy, Hold, and Sell.
• Contineum is a clinical‑stage biotech whose lead asset is PIPE‑791 (an LPA1R inhibitor for IPF and progressive MS); it reported EPS of ($0.49) beating estimates by $0.01 and has a market cap of about $498 million.

Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report)'s share price was up 8.7% during trading on Wednesday . The stock traded as high as $13.49 and last traded at $13.3980. Approximately 18,205 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 292,180 shares. The stock had previously closed at $12.33.

Analyst Ratings Changes

A number of research firms have weighed in on CTNM. Weiss Ratings reissued a "sell (d-)" rating on shares of Contineum Therapeutics in a report on Wednesday, January 21st. Morgan Stanley reaffirmed an "equal weight" rating and issued a $14.00 target price (down from $23.00) on shares of Contineum Therapeutics in a research report on Thursday, January 8th. Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Finally, Robert W. Baird boosted their price target on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the company an "outperform" rating in a research report on Friday, March 6th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $19.50.

Contineum Therapeutics Stock Up 8.1%

The firm has a 50-day simple moving average of $13.99 and a 200 day simple moving average of $12.29. The company has a market cap of $497.56 million, a price-to-earnings ratio of -6.11 and a beta of 1.07.

Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.01. As a group, research analysts expect that Contineum Therapeutics, Inc. will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio acquired a new stake in shares of Contineum Therapeutics during the first quarter worth about $27,000. Qube Research & Technologies Ltd purchased a new stake in Contineum Therapeutics during the 2nd quarter valued at approximately $43,000. China Universal Asset Management Co. Ltd. acquired a new stake in Contineum Therapeutics during the 4th quarter worth approximately $43,000. Marex Group plc acquired a new stake in Contineum Therapeutics during the 2nd quarter worth approximately $45,000. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Contineum Therapeutics in the second quarter valued at approximately $76,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.